Climate Neutrality in the Biopharma Industry, How Do We Get There?

by Lynn Stephenson, PhD | October 13, 2023

Hand,Of,Human,Holding,Earth,With,Esg,Icon,For,Environment

The annual Lancet Countdown on health and climate change reported that the healthcare industry contributes ~5% of global greenhouse gas emissions with approximately half coming from healthcare supply chains.  According to Biopharma International, without rapid decarbonization, the industry is on track to triple those emissions by 2050.   Healthcare companies are acting to reduce their climate impact and they are looking to their suppliers to help them meet their climate goals. To address these challenges, suppliers to the healthcare industry need to become more green, more efficient, and more circular.

How do we get there?

For the Life Science industry, meeting these goals will require a transformation in strategy that embeds sustainability principles into business decisions. At

Merck
MilliporeSigma
, we have set the ambitious goal to be climate neutral by 2040 and to leverage our expertise, experience, and partnerships to be a sustainability multiplier for our customers and collaborators.  In the first edition of the DCAT Sustainability eBook, Darren Verlenden, Head of Process Solutions and Ivan Donzelot, Head of Integrated Supply Chain, were recently featured in the first edition of the DCAT Sustainability eBook which focused on initiatives to improve sustainability in the Bio/Pharmaceutical supply chain.  They share examples of how we have operationalized sustainability into our business processes and how the alignment of business and supply chain goals, with the support of the Life Science Sustainability team, is one of the keys to the successes we are seeing with these efforts.

Want to learn more?

Download the DCAT eBook!

BioProcessing Supply Security Senior Marketing Manager

BioProcessing Supply Security Senior Marketing Manager

Lynn Stephenson, PhD, joined

MilliporeSigma
Merck KGaA, Darmstadt, Germany
, then Sigma-Aldrich, after completing a post-doctoral fellowship at Washington University in Immunology. She has experience in the In Vitro Diagnostics and Bioprocessing markets with roles that include product management, program management, and marketing with focuses on supply chain, quality and regulatory topics.

Related Posts

Vaccine Maker’s Toolkit: Strategies For Manufacturing And Supply Management

This collection of insights, produced through a partnership between

Merck KGaA, Darmstadt, Germany
,[geot_filter region="north-america" country=""...

Coming Full Circle with Biopharma Recycling

This post discusses the environmental challenges posed by the Biopharmaceutical industry's heavy reliance on single-use systems and the...

On demand Webinar mRNA – POWERING LIFE CHANGING THERAPIES

In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and...

Improved endotoxin removal using ecofriendly detergents for intensified plasmid capture

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with...

Bioprocessing operators in a closed processing CNC space

Are you OPEN to CLOSE your bioprocess?

In this webinar, you will: •Understand the main drivers and benefits of closed processing in biopharma, including facility...

Neglected Tropical Diseases — Improving the Manufacturing Paradigm for a Novel Recombinant Protein Vaccine

Vaccine Development collaboration: from Schistosomiasis to COVID-19 vaccine.

Scroll to Top